This is a major source of cardiovascular morbidity and mortality. We have never been able to treat lipoprotein(a) until now.” ...

Heart disease experts are hailing the results of a clinical trial showed a strongly positive performance by a drug that ...

An experimental drug could be game-changing for millions of Americans with a higher genetic risk of cardiovascular disease.

We know having high cholesterol isn't good for our health, but new research has found people who have low levels of "bad" ...

Monday is lipoprotein(a) awareness day. ABC News chief medical correspondent Dr. Tara Narula shares what you need to know.

Eli Lilly on Sunday said the Phase 2 study of lepodisiran, designed to lower the production of lipoprotein (a), or lp (a), met its primary endpoint, reducing lp (a) levels by an average of 93.9% over ...

Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) ...

Lilly's drug is one of several being tested to treat high Lp(a), a risk factor for heart disease that affects an estimated ...

Lowering your “bad” cholesterol might be doing more than just protecting your heart, it could also be safeguarding your brain ...

A single dose of an experimental drug dramatically reduced levels of a deadly form of cholesterol, often thought to be ...

Corporation highlighted key data presentations at ACC.25 showcasing the mechanistic activity of eicosapentaenoic acid, EPA, on ...